AJP - Heart Journal of Applied Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 294: H570-H578, 2008. First published December 14, 2007; doi:10.1152/ajpheart.01324.2007
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/2/H570    most recent
01324.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Archer, S. L.
Right arrow Articles by Weir, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Archer, S. L.
Right arrow Articles by Weir, E. K.

INVITED REVIEW

Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1{alpha}-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer

Stephen L. Archer,2 Mardi Gomberg-Maitland,2 Michael L. Maitland,3 Stuart Rich,2 Joe G. N. Garcia,1 and E. Kenneth Weir4

1Department of Medicine, Sections of 2Cardiology and 3Hematology/Oncology, University of Chicago, Chicago, Illinois; and 4Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota

Pulmonary arterial hypertension (PAH) is a lethal syndrome characterized by vascular obstruction and right ventricular failure. Although the fundamental cause remains elusive, many predisposing and disease-modifying abnormalities occur, including endothelial injury/dysfunction, bone morphogenetic protein receptor-2 gene mutations, decreased expression of the O2-sensitive K+ channel (Kv1.5), transcription factor activation [hypoxia-inducible factor-1{alpha} (HIF-1{alpha}) and nuclear factor-activating T cells], de novo expression of survivin, and increased expression/activity of both serotonin transporters and platelet-derived growth factor receptors. Together, these abnormalities create a cancerlike, proliferative, apoptosis-resistant phenotype in pulmonary artery smooth muscle cells (PASMCs). A possible unifying mechanism for PAH comes from studies of fawn-hooded rats, which manifest spontaneous PAH and impaired O2 sensing. PASMC mitochondria normally produce reactive O2 species (ROS) in proportion to PO2. Superoxide dismutase 2 (SOD2) converts intramitochondrial superoxide to diffusible H2O2, which serves as a redox-signaling molecule, regulating pulmonary vascular tone and structure through effects on Kv1.5 and transcription factors. O2 sensing is mediated by this mitochondria-ROS-HIF-1{alpha}-Kv1.5 pathway. In PAH and cancer, mitochondrial metabolism and redox signaling are reversibly disordered, creating a pseudohypoxic redox state characterized by normoxic decreases in ROS, a shift from oxidative to glycolytic metabolism and HIF-1{alpha} activation. Three newly recognized mitochondrial abnormalities disrupt the mitochondria-ROS-HIF-1{alpha}-Kv1.5 pathway: 1) mitochondrial pyruvate dehydrogenase kinase activation, 2) SOD2 deficiency, and 3) fragmentation and/or hyperpolarization of the mitochondrial reticulum. The pyruvate dehydrogenase kinase inhibitor, dichloroacetate, corrects the mitochondrial abnormalities in experimental models of PAH and human cancer, causing a regression of both diseases. Mitochondrial abnormalities that disturb the ROS-HIF-1{alpha}-Kv1.5 O2-sensing pathway contribute to the pathogenesis of PAH and cancer and constitute promising therapeutic targets.

hypoxia-inducible factor-1{alpha}; nuclear factor-activating T cells; voltage-gated potassium channels; fawn-hooded rats; mitochondrial fusion; pyruvate dehydrogenase kinase; lung cancer; reactive oxygen species; mitochondrial electron transport chain



Address for reprint requests and other correspondence: S. L. Archer, Univ. of Chicago, Sect. of Cardiology, MC 6080, 5841 S. Maryland Ave., Chicago, IL 60637 (e-mail: sarcher{at}medicine.bsd.uchicago.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. S. Wolin
Reactive oxygen species and the control of vascular function
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H539 - H549.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Rohwer, M. Welzel, K. Daskalow, D. Pfander, B. Wiedenmann, K. Detjen, and T. Cramer
Hypoxia-Inducible Factor 1{alpha} Mediates Anoikis Resistance via Suppression of {alpha}5 Integrin
Cancer Res., December 15, 2008; 68(24): 10113 - 10120.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
G. Marsboom and S. L. Archer
Pathways of Proliferation: New Targets to Inhibit the Growth of Vascular Smooth Muscle Cells
Circ. Res., November 7, 2008; 103(10): 1047 - 1049.
[Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. R. Khawaja, M. Carre, H. Kovacic, M. A. Esteve, and D. Braguer
Patupilone-Induced Apoptosis Is Mediated by Mitochondrial Reactive Oxygen Species through Bim Relocalization to Mitochondria
Mol. Pharmacol., October 1, 2008; 74(4): 1072 - 1083.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.